Abionyx Pharma annual stock-based compensation
2020
2021
2022
2023
2024
2025
Abionyx Pharma Stock-Based Compensation Growth & History (ABNX)
Abionyx Pharma's stock-based compensation was €792,000 for fiscal 2025.
View full Abionyx Pharma company overviewAbionyx Pharma annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | €792,000 | €166,000 | +26.52% |
| 2024 | 2024-12-31 | €626,000 | €606,000 | +3030.00% |
| 2023 | 2023-12-31 | €20,000 | −€486,000 | −96.05% |
| 2022 | 2022-12-31 | €506,000 | −€309,000 | −37.91% |
| 2021 | 2021-12-31 | €815,000 | €717,000 | +731.63% |
| 2020 | 2020-12-31 | €98,000 | — | — |
Abionyx Pharma stock-based compensation trends
Over the last five fiscal years, Abionyx Pharma's stock-based compensation increased from €98,000 to €792,000, a change of €694,000.
About the metric
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
Calculation and source
reported stock-based compensation
TickerStat standardizes share-based compensation reported in company official filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Abionyx Pharma source filings ↗